Cadila Healthcare gets USFDA nod
DSIJ Intelligence / 20 Sep 2016
The company has informed exchanges that its oral solid dosage drug manufacturing plant located at SEZ Ahmedabad has received an establishment inspection report (EIR) from the USFDA following the inspection carried out in January 2016.
Cadila Healthcare has informed both the exchanges about getting a USFDA nod.
The company has informed exchanges that its oral solid dosage drug manufacturing plant located at SEZ Ahmedabad has received an establishment inspection report (EIR) from the USFDA following the inspection carried out in January 2016.The receipt of EIR indicates the successful closure of the inspection points (483s) raised, according to the company management. The company also mentioned that this manufacturing facility is a separate manufacturing unit and does not form a part of Moraiya formulations manufacturing facility.
The stock is buzzing on bourses by clocking gains of Rs 12.25 per share or 3.16 per cent on Tuesday- intraday basis . Cadila is trading at Rs 399 per share. Over one year the stock has traded flat and is up by 0.28 per cent.